The September 2026 medical-device mass-tort update shows active litigation, major bellwether verdicts, and mixed settlement signals—not one industry-wide event. A mass tort combines many individual injury claims involving the same product or evidence, often through multidistrict litigation, or MDL. The key developments include a $40 million Bard PowerPort verdict, an $88 million Covidien hernia-mesh verdict, unresolved device claims after major settlements, and a new spinal-lead recall that shows why recalls and lawsuits must be analyzed separately.
Table of Contents
- What changed in the September 2026 litigation picture?
- Why does the Bard PowerPort verdict matter?
- What does the Covidien hernia-mesh verdict mean for claimants?
- Which device cases have settlement limits or unresolved claims?
- Does a device recall prove a mass tort?
What changed in the September 2026 litigation picture?
The U.S. Judicial Panel on Multidistrict Litigation's September 1 release is the relevant reporting cutoff for the national mdl snapshot. It does not announce a single medical-device event or resolve every pending case. Instead, it provides a point-in-time view of federal proceedings.
The September 1, 2026 JPML pending-MDL release The Bard implanted-port-catheter litigation remains one of the largest active device MDLs. MDL No. 3081, pending in the District of Arizona, had 3,734 actions pending on September 1. That number measures filed federal actions, not the number of injured people nationwide. It also does not predict how many claims will settle, proceed to trial, or be dismissed.
Why does the Bard PowerPort verdict matter?
A nine-person Arizona federal jury awarded Kimberly Divelbliss $40 million after finding Bard liable on design-defect and failure-to-warn claims involving a fractured PowerPort catheter. The verdict is a significant bellwether result because it gives both sides evidence about how a jury may evaluate the product, injury, warnings, and causation. Wagstaff & Cartmell's report on the $40 million Bard verdict A bellwether trial does not automatically establish the value of other claims. Each claimant still faces product-identification, medical-causation, injury, damages, and procedural issues.
The next scheduled Bard trials provide the more immediate valuation signal. The case-management schedule identifies Judy Hicks for trial beginning October 13 and Lloyd Sorensen for December 1, 2026. Those results may show whether the Divelbliss award reflects a broader pattern or an unusually strong set of facts. Bard Case Management Order No. 38.
What does the Covidien hernia-mesh verdict mean for claimants?
In the first Covidien hernia-mesh MDL bellwether, a Massachusetts federal jury awarded Larry and Tammy Patterson $88 million after finding that Symbotex mesh carried inadequate warnings. Medtronic indicated that it would pursue post-trial motions and an appeal. The Patterson bellwether verdict report The award is important evidence, but it does not bind other claimants or set their damages.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
The reporting plaintiffs' counsel described the bellwether as a test of common evidence, and the verdict remains subject to appeal. Readers should therefore avoid treating $88 million as a standard payout estimate. The result may affect settlement discussions, trial strategy, and how lawyers assess warning and causation evidence, but it does not guarantee recovery in another case.
Which device cases have settlement limits or unresolved claims?
Becton, Dickinson and Company reported in 2024 that an agreement resolved the "vast majority" of its hernia litigation in Rhode Island and the Ohio federal MDL. The confidential agreement did not include an admission of liability, and unresolved cases remained subject to defense. Philips reported that its U.S. Respironics personal-injury and medical-monitoring resolution is capped at $1.1 billion.
Remaining litigants must satisfy a Lone Pine order, which requires prima facie evidence of injury, exposure, and causation or creates a risk of dismissal. Philips' Respironics resolution FAQ These developments show why a headline settlement does not necessarily end every related case. A claimant's position may depend on whether the claim falls within the agreement, whether required evidence was submitted, and whether the court's deadlines and proof requirements were met. Before assuming a case is covered, a reader should check:.
- The exact device, model, and alleged failure.
- Medical records linking the device to the claimed injury.
- Implant, explant, revision, and treatment dates.
- Any court order, settlement notice, or proof deadline.
- Whether the claim involves personal injury, medical monitoring, or another theory.
Does a device recall prove a mass tort?
No. The FDA's September 3, 2026 Class I recall of unused Boston Scientific Infinion CX spinal-cord-stimulator leads reported 1,081 serious injuries and no deaths, but it did not affect leads that had already been implanted. The recall demonstrates the seriousness of a device problem, yet it does not by itself prove liability, widespread compensable injury, or the existence of a mass tort.
FDA's Infinion CX recall notice For a potential claimant, the practical question is not simply whether a product was recalled. It is whether the person used the specific product, experienced a qualifying injury, and can connect that injury to the alleged defect or warning problem. The most important developments to watch next are the scheduled Bard bellwether trials, post-trial proceedings and any appeal in the Covidien case, and court deadlines governing unresolved claims in existing settlements.
You Might Also Like
- Pharmaceutical Lawsuits Mass Tort Litigation August 2026 Update: What Changed, Why It Matters, and What to Watch Next
- Legal Glossary Mass Tort Litigation September 2026 Update: What Changed, Why It Matters, and What to Watch Next
- Injuries Mass Tort Litigation September 2026 Update: What Changed, Why It Matters, and What to Watch Next